ArticleBrain and behavior2025
Chronic Quetiapine Administration Has a Therapeutic Effect on Anxiety and Depression-Like Behavior in a Chronic Unpredictable Mild Stress (CUMS) Rat Model.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quetiapine ameliorates sensorimotor gating, recognition memory, and neuroendocrine plasticity in chronic stress-induced female rats.Metabolic brain disease · 2026Article
- Chronic Quetiapine Administration Has a Therapeutic Effect on Anxiety and Depression-Like Behavior in a Chronic Unpredictable Mild Stress (CUMS) Rat Model.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe mechanisms underlying quetiapine's effects on anxiety- and depression-like behaviors induced by chronic unpredictable mild stress (CUMS) remain unclear. This study aimed to evaluate the therapeutic potential of quetiapine in a rat model of CUMS. MATERIALS AND
methodsIn the first experiment, 40 adult female Wistar albino rats were randomly assigned to either a control group (non-stressed, n = 20) or a chronic unpredictable mild stress (CUMS) group (n = 20) for 28 consecutive days. To evaluate stress-related behavioral changes, the sucrose preference test (SPT), fecal boli count, and elevated plus maze (EPM) test were conducted on days 29 and 30. In the second experiment, on day 30, animals from both initial groups were further divided into four experimental groups (n = 10 per group): (1) Control (1 mL saline, i.p., for 30 days), (2) Quetiapine (QET; 10 mg/kg/day, i.p., for 30 days), (3) CUMS only (no treatment), and (4) CUMS + QET (10 mg/kg/day, i.p., for 30 days). Following treatment, behavioral assessments (SPT, forced swim test (FST), elevated plus maze test (EPM), and fecal boli count) were conducted on days 61, 62, and 63.
resultsCUMS induced significant anxiety- and depression-like behaviors. Chronic quetiapine administration (10 mg/kg/day) reversed these behavioral deficits, suggesting antidepressant and anxiolytic effects.
conclusionQuetiapine alleviates CUMS-induced anxiety and depression-like behaviors, supporting its potential as both monotherapy and adjunctive treatment in stress-related disorders. Further research should explore sex differences, dose-response effects, biochemical or molecular markers, and other stress paradigms to optimize clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.